RxDoctor Payments Data

Humza Quadri, MD

Family Medicine · Saint Louis, MONPI 1457912255

Payments from drug & device makers

$3,722in general payments, 2019–2025

Across 200 payments — averaging $18.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$682
  • Novo Nordisk$355
  • Novartis$330
  • Lilly USA, LLC$313
  • Pfizer$236
  • Johnson & Johnson$189
  • plus $2K from 24 others

What the payments were for

  • Food & beverage$3,722100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,722 in reported general payments places this provider in the 80th percentile of 2,203 family medicine providers in Missouri.

See all family medicine providers in Missouri

Medicare billing

Part B allowed, 2024
$90,292
Medicare patients
293
Services billed
1,224

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban45$38,479
JardianceEmpagliflozin24$27,911
FarxigaDapagliflozin Propanediol39$26,528
MounjaroTirzepatide24$23,846
LinzessLinaclotide44$22,909
TrulicityDulaglutide22$22,795
OzempicSemaglutide18$19,075
JanumetSitagliptin Phos/Metformin Hcl16$12,583
JanuviaSitagliptin Phosphate13$12,219
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$11,139
MyrbetriqMirabegron18$11,046
VascepaIcosapent Ethyl20$7,701
Breo ElliptaFluticasone/Vilanterol18$6,974
Lidocaine43$4,498
Albuterol Sulfate HfaAlbuterol Sulfate81$2,533

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$313$46,64146 claims
PfizerEliquis$236$38,47945 claims
Boehringer IngelheimJardiance$92$27,91124 claims
AstraZenecaFarxiga$132$26,52839 claims
MerckJanumet, Januvia$134$24,80229 claims
AbbVieLinzess$682$22,90944 claims
Novo NordiskOzempic$355$19,07518 claims
GSKTrelegy Ellipta, Breo Ellipta$65$18,11433 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,203 family medicine providers in Missouri.

Other family medicine in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →